Pharmafile Logo

Combination therapies in oncology: The benefits of integrated insights

14 June 2018
11am EDT | 8am PDT | 4pm BST | 5pm CE


In association with Pharmaceutical Executive

Register now: https://bit.ly/2L80Tme

Most experts believe combination therapies to be the future of oncology treatment. But with a number of new compounds approved and hundreds more in development, it’s difficult for many to identify which combinations and in what sequence, will form future treatment paradigms. In addition, the rising costs of newer agents and increased cost pressure creates an environment ripe for payer management.

In this webinar, pharma market research experts Anthony Greenwood, Dr Chris Gaj and  Brett Gardiner will look at the challenges and opportunities for effectively launching combination therapies across tumor types and, referencing their experience in oncology, demonstrate how integrated insights from payers, KOLs, community oncologists and patients can help support bio-pharma companies with oncology assets in all stages of clinical development.

Key Learning Objectives:

Delegates will:

  • Learn about the major themes, challenges and opportunities for marketing an oncology therapy in combination, including clinical trial design, pricing, sequencing and product attributes, amongst others
  • Understand implications of combining therapies from more than one manufacturer, anticipated pricing challenges and considerations for indication expansion
  • Understand the payer environment in oncology across the US and EU and uncover what evidence payers are looking for to make decisions about combination therapies
  • Understand how KOLs see oncology market evolving and how combination therapies will be utilized
  • Understand what effect patient characteristics may have on eventual treatment choice
  • Learn how integrated insights across all stakeholder groups can benefit launch strategies

Register now: https://bit.ly/2L80Tme

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Case Study: Oncology diagnostic biomarker landscaping study

The challenge:Our client needed to understand moleculardiagnostic testing growth opportunities for a new biomarker in oncology. They wanted to understand the current market landscape, identify potential leverage points that would maximise use of the biomarker...

Research Partnership publishes 2016 Living with RA reports

Research Partnership has published new Living with rheumatoid arthritis (RA) EU and US market reports for 2016.

Article: The Art of Storytelling in Pharma Market Research

Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director

Video: Immuno-oncology therapies

Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high price...

The challenges of conducting effective pharmaceutical market research in emerging markets

Published in Quirk's Marketing Research Review, April 2016, By Marc Yates, Director of Emerging Markets

Research Partnership appoints Director and Head of Business Analytics, North America

Tom has been appointed a Director in our Philadelphia office. He has over 25 years’ experience in healthcare research and has an extensive background in both quantitative and qualitative research,...

Article: The Art of Storytelling in Pharma Market Research

Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director

Event: EphMRA Annual Conference 2016

Frankfurt, Germany 21 - 23 June 2016

The challenges of conducting effective pharmaceutical market research in emerging markets

Published in Quirk's Marketing Research Review, April 2016, By Marc Yates, Director of Emerging Markets

Blog: Viewing facility research, re-imagined

As technology has evolved, so too has the world of qualitative research